trending Market Intelligence /marketintelligence/en/news-insights/trending/YJv6ArxNkJGhxu7-VSSvLg2 content esgSubNav
In This List

Bausch, Teva Pharmaceuticals settle patent dispute over colitis drug Apriso

Blog

Funding Social and Affordable Housing: A Credit Perspective

Blog

Global M&A By the Numbers: Q2 2021

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times


Bausch, Teva Pharmaceuticals settle patent dispute over colitis drug Apriso

Bausch Health Companies Inc. and its Salix Pharmaceuticals Ltd. unit agreed with Teva Pharmaceuticals USA Inc. to resolve litigation relating to the extended-release formulation of Apriso.

Apriso, or mesalamine, is used to treat inflammatory bowel disease ulcerative colitis in adults.

As part of the agreement, Bausch will grant Teva a nonexclusive license to market a generic version of the drug in the U.S., starting Oct. 1, 2021, and it will not make any financial payments or other transfers.

The patent for Apriso is set to expire in 2030.

Bausch, which acquired the rights to Apriso through its acquisition of Salix in April 2015, said it will continue to vigorously defend its intellectual property.

Bausch also modified its prior sub-license agreement for the drug with Lupin Pharmaceuticals Inc.